A carregar...
The End Point Is Just the Beginning
Clinical trials to support registration of new drugs are arduous, lengthy, and expensive. Diabetes treatment trials intended to seek indications for glycemic control are facilitated by the regulatory acceptance of glycosylated hemoglobin (A1C) as a validated intermediate efficacy end point. However,...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Diabetes Technology Society
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3208893/ https://ncbi.nlm.nih.gov/pubmed/22027330 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|